BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

The company, which partnered with Pfizer to develop the first Covid-19, vaccine approved for use in the U.S. says its Omicron-adapted vaccines should be ready for delivery as early as October.

BioNTech Misses Earnings Estimates

BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October, which will help spur demand in the fourth quarter, said the German biotech firm as it reaffirmed its vaccine revenue guidance for the year on Monday.

BioNTech expects Omicron-adapted vaccine deliveries as soon as October

The company reports second-quarter earnings of €6.45 a share on revenue of €3.2 billion.

BioNTech Earnings and Revenue Miss Expectations

The U.S.-listed shares of Germany-based BioNTech SE BNTX, +1.48% sank 8.2% in premarket trading Monday, after the biotechnology company and Pfizer Inc. PFE, -1.18% partner in developing a COVID-19 vaccine reported second-quarter profit and revenue that fell below expectations but affirmed its full-year COVID-19 revenue outlook. Net income dropped to EUR1.67 billion ($1.70 bln), or EUR6.45 a share, from EUR2.79 billion, or EUR10.77 a share, in the year-ago period.

BioNTech stock sinks more than 8% after profit, revenue fall below expectations

Conference call and webcast scheduled for August 8, 2022, at 8:00 am ET (2:00 pm CET)

BioNTech Announces Second Quarter Financial Results and Corporate Update

MAINZ, Germany, and COPENHAGEN, Denmark, August 5, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Genmab A/S (“Genmab”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under this expansion, BioNTech and Genmab will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options for cancer patients.

BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Genmab - ADR

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint develop

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

Moderna

Novavax

The booster market might be a long-term source of revenue.

Could the Fall Booster Market Boost Vaccine Stocks?

Pfizer

Moderna is still prevailing in the omicron booster market in at least one important way.

Why Pfizer and BioNTech Are Beating Moderna in the Omicron Booster Market

Moderna and BioNTech are the two mRNA giants behind the dominant COVID vaccines SpikeVax and Comirnaty. The two companies have a great deal in common, and the share prices typically track very close to one another.

Moderna And BioNTech: I Back The Former To Drive Share Price Upside In 2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is BioNTech (BNTX) a Great Value Stock Right Now?

Public Storage

These stocks have the potential to outperform in the second half given their strong financials.

These 2 Companies Are Banking 50% Profits Despite the Bear Market

Pfizer Inc. PFE, +1.02% and German partner BioNTech SE BNTX, -1.63% said Wednesday they have started a Phase 2 study to evaluate an enhanced COVID-19 vaccine aimed at the original strain of the virus and the omicron variant that seeks to create a more robust and longer-lasting immune response. The new bivalent vaccine called BNT162b5 will be tested in a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response.

Pfizer and BioNTech launch study to evaluate COVID-19 vaccine targeting original virus strain plus omicron variant

NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing the magnitude and breadth of the immune response that could better protect against COVID-19.

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

Tonix Pharmaceuticals Hld

Monkeypox cases are significantly growing during the past few months, especially catalyzed by an increase in international travel. On July 23, WHO declared the Monkeypox spread as a global health emergency, indicating the agency's high degree of concern around the severity of the disease and its spread.

Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic

CureVac B.V

COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.

BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

Mainz, Germany, July 25, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2022 on Monday, August 8th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2022.

BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022

BioNTech and Pfizer Inc (NYSE:PFE) are reportedly close to reaching an agreement with the European Union to extend Covid-19 vaccine deliveries until 2024, slowing deliveries amid a glut of shots in the bloc. A contract has been signed for up to 1.8bn doses of the messenger RNA (mRNA) shot, including variant-adapted vaccines, though the contract only extends to 2023.

BioNTech and Pfizer in talks to delay Covid vaccine deliveries amid EU glut

Because of geopolitics, we have forgotten COVID, but in vain - the number of new cases is increasing, while the fall season has not even begun. As demand for vaccines picks up in the early fall, shares of vaccine manufacturers could rise again.

Buy BioNTech Stock - Ride The New Wave Of Covid

BioNTech snagged an upgrade Wednesday with an analyst saying "Covid fatigue" has obscured its non-pandemic efforts. The post Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade appeared first on Investor's Business Daily.

Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade

The average of price targets set by Wall Street analysts indicates a potential upside of 47.9% in BioNTech SE Sponsored ADR (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does BioNTech SE Sponsored ADR (BNTX) Have the Potential to Rally 48% as Wall Street Analysts Expect?

Merck

Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.

PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents

CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.

BioNTech sued by CureVac over its mRNA technology

CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

News for BioNTech SE Stock (BNTX)